| ||||||||||||||||||||
Tuesday 22 September 2009 CenterWatch Posting of the Breakthrough Cancer Pain Study CenterWatch Posting of the Breakthrough Cancer Pain Study. Click below links to find out more:Canton : Gabrail Cancer Center Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study) Canton : Gabrail Cancer Center This is a Multicenter, Randomized, Placebo-Controlled research study to evaluate the effectiveness of ARX-F02 (Sublingual Sufentanil NanoTab™) versus placebo ("sugar" pill) in the management of breakthrough pain in cancer patients. The drug being evaluated in this study, Sufentanil has already been approved by the FDA for intravenous (IV) anesthetic use during operative procedures. It has not yet been approved for sublingual (under the tongue) use, which is what this study is evaluating. Dover : Gabrail Cancer Center Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. (SPRAY study)
News Categories |
|
.png){kind=icon}
